



Windlas Biotech Limited

Reg. Off.: 40/1, Mohabewala Industrial Area
Dehradun, Uttarakhand 248 110, India
Tel.:+91-135-6608000-30, Fax:+91-135-6608199

Corp. Off.: 705-706, Vatika Professional Point, Sector-66,
Golf Course Ext. Road, Gurgaon, Haryana 122 001, India
Tel.:+91-124-2821030

CIN-L74899UR2001PLC033407

February 08, 2023

To
Listing / Compliance Department
BSE Limited
Phiroze Jeejeebhoy Towers
Dalal Street, Mumbai – 400 001

To
Listing / Compliance Department
National Stock Exchange of India Limited
Exchange Plaza, C-1, Block G
Bandra Kurla Complex
Bandra (E), Mumbai – 400 051

BSE CODE: 543329

NSE SYMBOL: WINDLAS

Dear Sir/ Madam,

Subject: Press Release - Appointment of Chief Executive Officer (CEO)

Pursuant to Regulation 30 the SEBI (Listing Obligations and Disclosure Requirements), Regulations 2015, this is to inform you that the Board of Directors of the Company has approved the appointment of Ms. Komal Gupta from the Chief Financial Officer (CFO) to the Chief Executive Officer (CEO) of the Company with effect from 08th February, 2023.

The Company is in the process of appointing the new Chief Financial Officer. In the interim, Ms. Komal Gupta will continue to assume the responsibilities of a Chief Financial Officer.

Mr. Hitesh Windlass and Mr. Manoj Kumar Windlass will continue as Managing Director and Joint Managing Director, respectively.

A press release issued by the Company in this regard, is enclosed for necessary dissemination. You are requested to take note of the above and arrange to bring this to the notice of all concerned.

Thanking you,

Yours faithfully,

For Windlas Biotech Limited

Ananta Narayan Panda
Company Secretary & Compliance Officer

Press Release**Windlas Biotech appoints Ms. Komal Gupta as CEO**

Wednesday, 08th February 2023, Gurugram: Windlas Biotech Limited (Windlas), one of the top five players in the domestic pharmaceutical formulations contract development and manufacturing organization (“CDMO”) industry in India, announced the appointment of Ms. Komal Gupta as CEO of the company. The Company is in the process of appointing the new Chief Financial Officer shortly and in the interim, Ms. Komal Gupta will continue as Chief Financial Officer.

Ms. Komal Gupta acted as the CFO of Windlas Biotech Limited and has an extensive experience in the field of Finance, Accounts, Taxation, Business Finance, Treasury and Compliance. Prior to joining the Company, she has worked with Anand Automotives Group (Perfect Circle India Limited, Mahle Filters Limited, Corporate office Anand Automotive Systems Limited) and DSM Group (DSM Sinochem Pharmaceuticals India Pvt. Ltd., now Centrient Pharmaceuticals India Pvt. Ltd.).

Mr. Hitesh Windlass and Mr. Manoj Kumar Windlass will continue as Managing Director and Joint Managing Director, respectively.

Commenting on the appointment, Mr. Hitesh Windlass, Managing Director, said,

“We are delighted to appoint Komal to the position of CEO of Windlas Biotech. As we continue to accelerate our expansion strategy, her extensive industry experience and expertise in establishing long-lasting alliances will be invaluable.

Her remarkable skills and other operational disciplines have consistently contributed to the organization's fiscal prudence. We believe she will be the ideal leader to take on this role due to her extensive knowledge of our business and proven ability to achieve results consistently.”

On the appointment as CEO, Ms. Komal Gupta said,

“I am glad to move in more operational role as a CEO of the company. I am privileged to be given the opportunity to scale to the next level and remain committed to further strengthening the business excellency and DNA of Windlas. My experience of more than 7 years with the Company has allowed me to gain valuable insight in the day-to-day functioning which will enable me to further bring in operating efficiency. I look forward to working closely with Hitesh and Manoj on the Company's next phase of growth.”

About Windlas Biotech Limited

The company (Windlas) is amongst the top five players in the domestic pharmaceutical formulations contract development and manufacturing organization (“CDMO”) industry in India in terms of revenue. With over two decades of experience in manufacturing both solid and liquid pharmaceutical dosage forms and significant experience in providing specialized capabilities, including, high potency,

controlled substances and low solubility, the Company provides a comprehensive range of CDMO services ranging from product discovery, product development, licensing and commercial manufacturing of generic products, including complex generics, in compliance with current Good Manufacturing Practices (“GMP”) with a focus on improved safety, efficacy and cost.

Safe Harbor

Statements in this document relating to future status, events, or circumstances, including but not limited to statements about plans and objectives, the progress and results of research and development, potential project characteristics, project potential and target dates for project-related issues are forward-looking statements based on estimates and the anticipated effects of future events on current and developing circumstances. Such statements are subject to numerous risks and uncertainties and are not necessarily predictive of future results. Actual results may differ materially from those anticipated in the forward-looking statements. The company assumes no obligation to update forward-looking statements to reflect actual results changed assumptions or other factors.

For more information please contact:



Windlas Biotech Limited

CIN: U74899UR2001PLC033407

Ms. Komal Gupta

Email: Komal@windlasbiotech.com

Contact no.: +91 124 2821034



Strategic Growth Advisors Pvt. Ltd.

CIN: U74140MH2010PTC204285

Mr. Jigar Kavaia / Mr. Chinmay Madgulkar

Email: jigar.kavaia@sgapl.net / chinmay.m@sgapl.net

Contact no.: +91 9920602034 / +91 9860088296